German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming ...

Despite a net loss, BioNTech SE (BNTX) remains focused on oncology advancements and maintains a strong financial position ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

Scientists project that by 2026 the results of clinical trials being conducted in 25 countries, including Spain, will be ...

German biotech BioNTech (Nasdaq: BNTX) saw its shares dip 3.4% to $101.44 today, after it reported financial results for the ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...